The mechanism of sPD1 action was assumed to be through binding to and preventing tumour cell PD-L1 from activating the endogenous PD-1 receptor, acting as a competitive inhibitor, but it could also function in vivo by preventing tumour associated macrophage-secreted PD-L1 or PD-L2. Here, CD274 is linked to neoplasm.